A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
An open label, single arm study to evaluate the study and efficacy of efalizumab in
combination with NB-UVB. Weeks 1-12 efalizumab will be administered once a week in
combination with NB-UVB three times per week. Weeks 13-24 efalizumab monotherapy will
continue. Weeks 25-36 subjects will be followed for safety.
Subjects with moderate to severe plaque psoriasis often require more than one therapy to
treat their disease. Because of the different mechanisms of action, it is thought that
combined efalizumab and NB-UVB may be more effective and have a more rapid onset than either
treatment alone.